Institute of Cancer Research, United Kingdom
179
33
52
61
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
5.6%
10 terminated/withdrawn out of 179 trials
85.9%
-0.6% vs industry average
16%
28 trials in Phase 3/4
23%
14 of 61 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (179)
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
Role: lead
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Role: lead
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Role: lead
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Role: collaborator
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Role: lead
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Role: collaborator
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Role: collaborator
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
Role: collaborator
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Role: lead
Pembrolizumab and Palliative Radiotherapy in Lung
Role: collaborator
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Role: lead
The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study
Role: lead
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Role: collaborator
Population Based Germline Testing for Early Detection and Prevention of Cancer
Role: collaborator
Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC
Role: lead
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
Role: lead
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
Role: lead
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Role: collaborator
Phase I Trial of Defactinib and VS-6766.
Role: lead
Molecular Studies and Clinical Correlations in Human Prostatic Disease
Role: collaborator